Tiziana Life Sciences PLC’s (TLSA) Lock-Up Period To End on May 20th

Tiziana Life Sciences’ (NASDAQ:TLSA) lock-up period will end on Monday, May 20th. Tiziana Life Sciences had issued 442,910 shares in its public offering on November 20th. The total size of the offering was $4,384,809 based on an initial share price of $9.90. After the expiration of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

TLSA opened at $8.18 on Monday. Tiziana Life Sciences has a 1-year low of $5.00 and a 1-year high of $12.17.

COPYRIGHT VIOLATION WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2019/05/13/tiziana-life-sciences-plcs-tlsa-lock-up-period-to-end-on-may-20th.html.

About Tiziana Life Sciences

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus.

Featured Article: Oversold

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply